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ess: z.zietkowski@wp.pSummary Ciclesonide is a novel, lung-activated, inhaled corticosteroid with once-
daily efficacy and potent anti-inflammatory activity. The aim of the study was to
compare the effect of ciclesonide and fluticasone propionate on exhaled nitric oxide
(FENO), pulmonary function, and other parameters used in clinical evaluation of
patients with mild allergic asthma. The study indicates that ciclesonide (in a daily
dose of either 80 or 160 mg) induces both a faster and stronger decrease of FENO in
comparison with fluticasone (100 mg twice daily). In both groups of patients treated
with ciclesonide, the highest decrease in FENO levels was observed after 2 weeks of
treatment. In the group of patients treated with fluticasone, this maximum effect
was not observed till 8 weeks. An improvement in spirometric indices was observed
in all groups studied. Statistical differences between the groups were not found;
however, there was a trend toward higher increase in the group receiving 160 mg of
ciclesonide. In all groups studied we observed clinical improvement (asthmatic
symptoms and consumption of rescue medication were reduced), but there were no
significant differences between these groups. Our results indicate that ciclesonide,
compared with fluticasone, has stronger anti-inflammatory activity in patients with
mild allergic asthma.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
7468373;
l (Z. Zietkowski).Introduction
Inhaled corticosteroids (ICS) are the most effective
drugs currently used to treat chronic asthma in
patients of all ages with differing degrees of
asthma severity. The benefits of long-term treat-
ment with ICS must be weighed against theed.
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treatment.1 The major aim in the development of
novel steroids is to design substances that have high
topical potency, but no or significantly reduced
systemic side effects.2 Effective on-site activation,
together with the unique pharmacokinetic proper-
ties of the active metabolite (including high plasma
protein binding and rapid systemic clearance), was
achieved when developing ciclesonide. Ciclesonide
is a new-generation non-halogenated glucocorti-
costeroid with high local anti-inflammatory
properties and essentially no oral bioavail-
ability. Activation of ciclesonide by endogenous
esterases occurs upon the ester cleavage in the
airways.3
The increased expression of inducible nitric oxide
synthase and elevated levels of exhaled nitric oxide
(FENO) are seen in asthmatic patients.
4 The con-
centration of exhaled NO correlates well with
inflammatory markers in bronchial biopsies and
bronchial lavage.5,6 Corticosteroid therapy reduces
FENO in a dose-dependent manner.
7 Clinical applica-
tions of FENO measurement include monitoring
compliance and response to treatment, disease
activity, and the prediction of acute exacerbations.
Recently the measurement of FENO has become a
more and more appreciable criterium for the
evaluation of bronchial inflammation, which is
helpful in the monitoring of anti-inflammatory
treatment, especially in patients with mild asthma,
because in these patients spirometric indices and
the clinical evaluation of symptoms have limited
application.8,9
In the clinical evaluation of the efficacy of
ciclesonide compared to other ICS, non-invasive
methods for estimating the inflammatory processes
could be useful. Thus, the aim of the study was to
compare the effect of ciclesonide (in a daily dose of
either 80 or 160 mg in the evening) and fluticasoneTable 1 Characteristics of study subjects.
Characteristics Dimension
Number of patients
Sex F/M
Age Years
Duration of symptoms Years
Allergic rhinitis
FEV1 before treatment L
% predicted
FEV1 after 12 weeks of the study L
% predicted
Data are presented as medians (ranges).propionate (100 mg twice daily in the morning and
evening) on exhaled nitric oxide, pulmonary func-
tion, symptoms score, use of rescue medication,
and asthma control in patients with mild allergic
asthma.Methods
Subjects
The study was conducted in a group of 35 patients
with mild allergic asthma. Asthma was diagnosed
according to the criteria recommended by the
GINA.10 The presence of allergy to common aller-
gens (house dust mite, trees, weeds, grasses, cat,
Alternaria, or Cladosporium) was demonstrated in
all patients by positive skin prick tests. The
characteristics of the studied patients are pre-
sented in Table 1. All patients had been in a stable
condition free from acute exacerbations and
respiratory tract infections during the past 4
weeks. Patients with other factors which could
change FENO levels (except for asthma, features of
atopy, or allergic rhinitis) were excluded from the
study. Patients were non-smokers and during
the last year have not been passive smokers. Before
the beginning of the study patients were treated
with inhaled steroids with a maximum daily dose of
250 mg fluticasone propionate or equivalent. During
the initial period (1–4 weeks), all patients were
treated with rescue medication (salbutamol) only.
The study was designed as a double-blind, double-
dummy, randomized, three arm parallel group
study (12-week treatment period).
The study protocol was approved by the Ethics of
Research Committee of the Medical University ofCiclesonide
80 mg group
Ciclesonide
160 mg group
Fluticasone
200 mg group
12 12 11
5/7 6/6 5/6
45.2710.9 42714 5177.6
16.1710.9 11710 1578.8
8 8 7
2.4570.67 2.570.58 2.470.72
78.6678.84 7377.36 79.376.7
3.170.59 3.1970.64 3.1170.81
96.7279.2 93.176.9 101.876.6
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every patient in the study.
Measurements
FENO was measured in all of the asthma patients by
the chemiluminescence technique using a Sievers
280i NO Analyzer (USA). Measurements were
performed at an expiratory flow of 50mL/s. To
produce a stable NO level for 3 s, the duration of
exhalation lasted at least 6 s. Repeated measure-
ments were performed until 3 values varied by less
than 10%. The mean value of the three measure-
ments was evidenced as the final FENO level.
11
The baseline spirometry was performed using
a MasterScreen Pneumo PC spirometer (Jaeger,
Germany). Spirometry was performed according to
ATS standards.12 Forced expiratory volume in 1 s
(FEV1) was evaluated. Before the examination the
patients did not take any medications that could
change spirometry results. The highest value from
three technically satisfactory attempts was at-
tached. All measurements were performed be-
tween 6 and 10 in the morning, thereby ensuring
that the tests were performed760min of the time
of the initial measurements at the treatment start.
At baseline, 2, 4, 8 and 12 weeks of treatment,
patients underwent FENO and spirometry measure-
ments.
Asthma symptom scores were recorded as the
sum of patients diary assessments of nighttime and
daytime symptoms. Nighttime symptoms were
classified by patient every morning on a 5-point
scale ranging from 0 (no symptoms) to 4 (bad night,
awake most of the night because of asthma).
Daytime symptoms were scored every evening on
a 5-point scale ranging from 0 (no symptoms) to 4Figure 1 The percentage reduction of FENO during therapy(asthma very bad, unable to carry out daily
activities as usual). Throughout the study, a daily
record of use of the rescue medication was
recorded in the diary.
Analysis
Because of the lack of normal distribution in some
variables, statistical analyses were compared using
non-parametric tests. Two groups comparisons
were done with the Wilcoxon test. All values
were expressed as means7SD, P-valueso0.05 were
considered significant.Results
Statistically significant differences in FENO and FEV1
values between the studied groups were not
observed before the beginning of the study. Figure
1 shows a significant reduction of FENO levels in all
investigated groups, measured during subsequent
visits—after 2, 4, 8, and 12 weeks of treatment, in
comparison with results from the baseline visit.
A statistically significant higher decrease of FENO in
both treatment groups receiving ciclesonide in
comparison to patients treated with fluticasone
was observed. In both ciclesonide treated groups,
an over 40% decrease of FENO was already being
observed after 2 weeks of treatment. Fluticasone
had significantly less influence on FENO, and max-
imal effect was not observed till after 8 weeks of
treatment. Among ciclesonide treated patients,
the effect of 160 mg on FENO was more pronounced
in comparison to 80 mg only after 12 weeks of
treatment, but the difference was not statistically
significant. Results concerning the measurementscompared with FENO before the beginning of treatment.
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Table 2 Changes in FENO levels in studied groups during therapy.
Exhaled nitric oxide (FENO) Dimension Ciclesonide
80 mg group
Ciclesonide
160 mg group
Fluticasone
200 mg group
Before treatment ppb 76.8746.5 104.7778.2 82.4754.8
Min/max 20/159 17/217 20/200
% of patients with FENOo30 ppb 30 20 20
After 2 weeks of treatment ppb 35.7731.36 49.3729.8 64.2749.7
% of patients with FENOo30 ppb 80 60 40
After 4 weeks of treatment ppb 32.8728.24 39.5722.61 60.4742.4
% of patients with FENOo30 ppb 80 60 40
After 8 weeks of treatment ppb 34.7730.84 36.5718.09 54.3737.9
% of patients with FENOo30 ppb 70 60 40
After 12 weeks of treatment ppb 33.5729.14 31.7719.9 50.9735.6
% of patients with FENOo30 ppb 80 70 40
Data are presented as medians (range).
FENOo30 ppb—acceptable asthma control.13
Figure 2 Changes in FEV1 during 12 weeks treatment
period.
Z. Zietkowski et al.1654of FENO levels in the studied groups, including
the percentage of patients with acceptable
asthma control (FENOo30 ppB),13 are presented in
Table 2.
The improvements in FEV1 were statistically
significant from the baseline (Po0:05) in all treated
groups. Significant differences between studied
groups were not found; however, there was a trend
toward higher increase in the group receiving
160 mg of ciclesonide (Fig. 2).
During the study in all treated groups the clinical
improvement, reduction of daily and night asth-
matic symptoms, and consumption of rescue
medication were observed (Po0:05). The analysis
of patients’ cards did not reveal significant differ-
ences between all the studied groups of patients
(Table 3). During the 12 weeks of the study,
exacerbations of asthma were not observed.Discussion
The results of the present study indicate that
ciclesonide exhibits both faster and stronger anti-
inflammatory effects compared with fluticasone in
patients with mild allergic asthma. Clinical im-
provement (symptoms score, consumption of res-
cue medication, spirometric indices) was observed
in all treated groups with no significant differences
between the two ciclesonide doses and fluticasone.
Leung et al.14 compared the effects of cicleso-
nide and fluticasone on allergic inflammation and
airway remodelling in a rat model of chronic
allergic asthma. Ciclesonide potently inhibited
chronic allergic inflammation, remodelling, and
bronchialhyperreactivity (BHR), while fluticasone
prevented airway inflammation, but had a lesser
effect on BHR.
Randomized clinical trials have confirmed the
efficacy of ciclesonide in the treatment of asth-
ma.15 Ciclesonide has been compared with other
ICS with documented efficacy. In comparison to
budesonide (400 mg once daily), ciclesonide (320 mg
once daily) resulted in better spirometric indices
and had a comparable effect on other parameters
used in clinical evaluation of asthmatic patients.16
The efficacy of ciclesonide (160 mg once daily)
and fluticasone (80 mg twice daily) has also been
evaluated. Both drugs reduce asthmatic symptoms
and the necessity for short-acting b2-agonists and
cause an increase of FEV1 in the same manner.
17
Only in a few clinical trials published so far has
ciclesonide been compared with other ICS using
non-invasive methods for evaluating the inflamma-
tory process. The measurement of exhaled nitric
oxide and the fraction of eosinophils in induced
sputum are very important in the assessment and
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Table 3 Changes in asthma daytime and nighttime symptoms scores and use of rescue medication vs baseline.
Characteristics Ciclesonide 80 mg group Ciclesonide 160 mg group Fluticasone 200 mg group
Baseline End of the
study
Baseline End of the
study
Baseline End of the
study
Daytime symptoms
score
1.2370.91 0.4370.52* 1.3271.13 0.4970.48* 1.4171.14 0.5770.64*
Nighttime symptoms
score
0.6170.32 0.2170.30* 0.5270.41 0.1970.28* 0.4770.57 0.1770.22*
Daily use of the rescue
medication
1.4470.72 0.5870.68* 1.2170.49 0.6070.55* 1.3870.68 0.6470.46*
Data are presented as medians (ranges).
*Po0:05 vs. baseline.
Data are presented as daily symptoms score and daily use of rescue medication during the last week of run in period and the last
week of treatment period.
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niess et al.18 have compared the effects of
ciclesonide and budesonide on lung function, air-
way responsiveness to inhaled AMP, the composition
of induced sputum, and the level of exhaled nitric
oxide in patients with mild asthma. In none of the
parameters studied did the changes differ signifi-
cantly between treated groups. These data suggest
that ciclesonide is equi-effective to budesonide;
however, a 2-week treatment period seems to be
too short to assess the anti-imflammatory activity
of both drugs. Lee et al.19 using the measurements
of FENO evaluated the safety of a 4-week treatment
of high doses of ciclesonide and fluticasone in
patients with moderate persistent asthma. In
another study these authors revealed the compara-
tive effect of ciclesonide (400 mg once daily) and
fluticasone (250 mg twice daily) used during 4
weeks, in patients with mild to moderate asthma.
However, the authors suggest that more studies to
evaluate the clinical efficacy of this therapy are
needed.20
One good point of our study seems to have been
the 12-week treatment period, which is sufficient
to evaluate the anti-inflammatory effects and
dosage of drugs, appropriate to the severity of
the disease.
A possible reason for the strong anti-inflamma-
tory effect of ciclesonide can be a solution
formulation for HFA-powered MDI with small parti-
cle size that extends the reach into the peripheral
airways, which have been shown to be sites of
significant inflammation even in asthma patients
who are asymptomatic.3,21 Ciclesonide also has low
oropharyngeal and high pulmonary deposition,
resulting in a high therapeutic index and low
potential for adverse events.22 Activation to a
potent metabolite with a high affinity for pulmon-ary glucocorticoid receptors, thereby providing
anti-inflammatory activity at the desired target
site, is also very important.23 Fatty acid conjuga-
tion of the active metabolite results in a depot
effect that extends the anti-inflammatory action.24
The original aspect of the trial is to reveal that
ciclesonide, which is safe and effective in asthma
treatment, also has a faster and stronger anti-
inflammatory effect than other currently used ICS.
More clinical studies using non-invasive methods
for assessing the long-term anti-inflammatory
effects of ciclesonide and other ICS are needed.Acknowledgments
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